AbbVie Inc. v. Hetero USA Inc.
1:15-cv-00889
Overview
Parties
Defendant
Hetero Labs Limited Unit-III NPE (University / Research)
Represented By
0 Attorneys ListedAbbVie Inc. Operating Company
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Polsinelli PC
222 Delaware Avenue, Suite 1101, Wilmington, DE 19801
Plaintiff
Abbvie Deutschland GMBH & Co. KG Operating Company
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Polsinelli PC
222 Delaware Avenue, Suite 1101, Wilmington, DE 19801
Counter Claimant
Hetero Labs Limited NPE (University / Research)
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
AbbVie Inc. v. Aurobindo Pharma Limited
AbbVie Inc. v. Amneal Pharmaceuticals, LLC
AbbVie Inc. v. Mylan Pharmaceuticals Inc.
AbbVie Inc. v. Hetero Labs Limited
AbbVie Inc. v. Aurobindo Pharma Limited
AbbVie Inc. v. Roxane Laboratories Inc.
AbbVie Inc. v. Mylan Pharmaceuticals Inc.
AbbVie Inc. v. Roxane Laboratories Inc.
Patents Involved
There are 11 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6037157
Method for improving pharmacokinetics
|
Filed: 1996-06-26
Issued: 2000-03-14
|
Expired (Term Ended)
Expires: 2016-06-26
|
|
|
US6703403
Method for improving pharmacokinetics
|
Filed: 2001-09-20
Issued: 2004-03-09
|
Expired (Term Ended)
Expires: 2016-09-09
|
|
|
US7148359
Polymorph of a pharmaceutical
|
Filed: 2005-05-04
Issued: 2006-12-12
|
Expired (Term Ended)
Expires: 2025-05-04
|
|
|
US7364752
Solid dispersion pharamaceutical formulations
|
Filed: 2000-11-10
Issued: 2008-04-29
|
Expired (Term Ended)
+688d PTA
Expires: 2022-09-29
|
|
|
US8025899
Solid pharmaceutical dosage form
|
Filed: 2004-08-25
Issued: 2011-09-27
|
Active (1.1 yrs remaining)
+1206d PTA
Expires: 2027-12-14
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).